Last reviewed · How we verify
pregabalin sustained-release tablets — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
pregabalin sustained-release tablets (pregabalin sustained-release tablets) — CSPC Ouyi Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| pregabalin sustained-release tablets TARGET | pregabalin sustained-release tablets | CSPC Ouyi Pharmaceutical Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- pregabalin sustained-release tablets CI watch — RSS
- pregabalin sustained-release tablets CI watch — Atom
- pregabalin sustained-release tablets CI watch — JSON
- pregabalin sustained-release tablets alone — RSS
Cite this brief
Drug Landscape (2026). pregabalin sustained-release tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/pregabalin-sustained-release-tablets. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab